MANISH PARANJPE,MD
mparanjp@stanford.edu | 937-430-6123

EDUCATION

Stanford University, Internal Medicine Residency 2023-Present
Harvard Medical School, M.D. Doctor of Medicine 2019-2023
Johns Hopkins University, B.A Biophysics
Phi Beta Kappa, Departmental Honors GPA 3.93, ACT 35 2014-2018
Hodson Trust Scholarship (Full tuition scholarship awarded to 10 students)

WORK EXPERIENCE

Patient Square Capital, Associate 09/2022-12/2023
- Fall Associate (Received full-time offer) responsible for deal diligence (25+ opportunities), financial modeling and supporting 3 portfolio companies (Kriya Therapeutics, Enavate, Apollo Therapeutics) across $4B PSC Fund I.
- Led scientific and business due diligence on 25+ potential growth equity and buyout investments across healthcare and life sciences including medical devices, diagnostics, life sciences tools, therapeutics, healthcare services, and providers (1 completed: Eargo)
- Built novel Markov chain Monte-Carlo based simulation model for therapeutics portfolio valuation using Python and R (now used by multiple partners for new investment diligence)

Neurona Health, Co-Founder and Advisor 04/2021-05/2023
- Cofounded early-stage startup to develop genetic and clinical risk prediction tools for pediatric diseases, advised by Dr. George Church
- Key milestones include raising seed funding led by Divergent Investments and publication of 10+ studies in top scientific journals (*JACC*, *JAHA*, *Nature Medicine*) https://www.neuronahealth.com/

Chardan Capital Markets, Associate 10/2020-04/2021
- Initiated coverage on 3 publicly traded companies in the gene therapy space including Taysha Gene Therapies (TSHA), MeiraGTx (MGTX), Prevail Therapeutics (acquired)
- Summarized key catalysts among 5 companies under coverage: Seres Therapeutics (MCRB), Passage Bio (PASG), Sio Gene Therapies (SIO), MGTX and TSHA
- Built proprietary AAV gene therapy valuation model using historical data from ~50 indications (now used across firm)
- Wrote industry notes following conversations with 10+ KOLs including Drs. George Church and Jennifer Doudna

RESEARCH EXPERIENCE

nference, Clinical Scientist 05/2020-12/2022
- Developed machine learning based method to identify optimal therapeutic strategy using RCT data in glioblastoma, now the basis for pre-clinical studies in collaboration with the Duke Tisch Brain Tumor Center
- Used NLP approaches to extract clinical notes, EMR and laboratory data into structured datasets, now used widely across the company and the basis of multiple large pharmaceutical collaborations and 2 SoWs

Broad Institute of Harvard and MIT, Graduate Student Researcher 09/2019-07/2022
- Co-author on 10 publications, 4 as 1st author
- Developed polygenic risk scoring tools for Alzheimer's disease
- Investigated placebo effects of multivitamin supplement (formed basis for NIH Health Professionals Fact Sheet for supplements)
- Research covered in popular press including *US News and World Report*, *The Guardian*, *WebMD*, *USA Today*

Johns Hopkins University, Undergraduate Researcher 2014-2019
- Co-author on 16 publications, 4 as 1st author, and 7 abstracts at top conferences (Keystone 2022, EMBO 2022, ASHG 2019)
- Leveraged transcriptomic and genomic to elucidate sex differences in neurodegenerative disease, awarded 2 undergraduate research grants totaling $7,500
- Use of single-cell RNA sequencing to investigate effects of early maternal immune activation on microglial activation

Selected Papers: 40+ abstracts and publications (8 as 1st author) in journals including Nature, Nature Communications and PLoS Genetics

1. **Paranjpe MD**, et al. Neurocognitive trajectory and proteomic signature of inherited risk for Alzheimer's disease. He Z, ed. *PLoS Genet.* 2022
2. **Paranjpe MD,** et al. Sex-Specific Cross Tissue Meta-Analysis Identifies Immune Dysregulation in Women With Alzheimer's Disease. *Front Aging Neurosci.* 2021
3. Hayes LN, … **Paranjpe MD**, et al. Prenatal immune stress blunts microglia reactivity, impairing neurocircuitry. *Nature*. 2022